NCT01044628 - Nocturnal Oxygen Therapy & Chronic obstructive pulmonary disease (COPD) / Emphysema

Study Design

Double-blind, placebo-controlled, randomized trial to determine, in patients with COPD who have nocturnal arterial oxygen desaturation without qualifying for long-term oxygen therapy, whether nocturnal oxygen provided for a period of 3 to 4 years would decrease mortality or the worsening of disease such that patients meet current specifications for long-term oxygen therapy.

Primary Outcome Measures:
Composite outcome: all-cause mortality or requirement for continuous oxygen therapy

Conclusion

The underpowered trial provides no indication that Nocturnal Oxygen has a positive or negative effect on survival or progression to long-term oxygen therapy in patients with COPD
Lacasse et al. 2020 NEJM 383: 1129-1138

…